Summit Therapeutics shares rise after AstraZeneca's $2B investment

AstraZeneca: AstraZeneca is a global biopharmaceutical company with a major focus on oncology, developing and commercializing medicines such as antibody-drug conjugates for various cancers. It maintains a broad portfolio in targeted cancer treatments and has pursued strategic collaborations to expand combination approaches. AstraZeneca recently entered into an equity investment and clinical collaboration agreement with Summit Therapeutics to jointly advance studies of their respective cancer drug candidates. Summit Therapeutics: Summit Therapeutics is a biopharmaceutical company focused on developing innovative oncology treatments, including the bispecific antibody ivonescimab targeting PD-1 and VEGF pathways. The company has advanced its pipeline through clinical collaborations and licensing agreements in cancer research. It recently announced a strategic equity investment and clinical partnership with AstraZeneca to accelerate development of combination cancer therapies. Pipeline Focus: The companies plan to explore ivonescimab alongside multiple AstraZeneca cancer medicines, including additional antibody-drug conjugates, to enhance treatment approaches across tumor types. Strategic Partnership: AstraZeneca and Summit Therapeutics have formed a clinical collaboration to evaluate combinations of their oncology treatments, starting with specific antibody-drug conjugates and bispecific antibodies in gastrointestinal cancers.